New ICH Guideline Marks Turning Point In Supporting Multi-Regional Pediatric Development

A new high-level draft ICH guideline issued is expected to reduce the likelihood of substantial differences among regions regarding acceptance of data generated in pediatric global drug development.

A new draft guideline issued by the International Council for Harmonisation to further support pediatric drug development is being regarded as an “important turning point for the benefit of children" because of its potential to affect a wide range of issues, such as regulatory convergence, drug development strategies, approach to R&D and designing of pediatric trials.

The draft guideline, on which stakeholder comments are being invited, is an addendum to the existing ICH E11 guidance on...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Clinical Trials

More from R&D

  • India Tightens Oversight Of CROs With Mandatory Registration

     
    • By 

    Contract research organizations (CROs) in India must gear up to comply with new registration requirements coming into effect in April 2025 that aim to enhance the quality and integrity of clinical trials, as well as of any bioavailability and bioequivalence studies conducted by them.

  • Clinical Trial Diversity Action Plans Need Timely FDA Feedback, Groups Say

     
    • By 

    The agency also should explain the potential consequences for sponsors if enrollment goals are not met, stakeholders say in comments on the DAP draft guidance. Some commenters urged the FDA to apply waiver criteria flexibly, especially for rare diseases.

  • How To Decarbonize Pharma R&D

     

    As the planet heats up and sea levels rise, the need to reduce carbon emissions is becoming ever more urgent. The life sciences industry is just one of many that are looking to cut the carbon it produces.